Adam D Cohen

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Anti-GITR antibodies--potential clinical applications for tumor immunotherapy
    David A Schaer
    Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue, New York, NY 10065, USA
    Curr Opin Investig Drugs 11:1378-86. 2010
  2. ncbi request reprint Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 139:224-33. 2007
  3. pmc Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity
    Adam D Cohen
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:4904-12. 2006
  4. pmc Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 5:e10436. 2010
  5. pmc Immune rejection of mouse tumors expressing mutated self
    Fei Duan
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:3545-53. 2009
  6. pmc Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope
    David A Schaer
    Swim Across America Laboratory, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, New York, United States of America
    PLoS ONE 6:e21214. 2011
  7. ncbi request reprint DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
  8. pmc Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
    Jose A Guevara-Patino
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1382-90. 2006
  9. pmc OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
    Daniel Hirschhorn-Cymerman
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 206:1103-16. 2009
  10. ncbi request reprint DNA vaccines against cancer
    Rodica Stan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Hematol Oncol Clin North Am 20:613-36. 2006

Research Grants

  1. Targeting GITR for Tumor Immunotherapy
    Adam Cohen; Fiscal Year: 2007

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Anti-GITR antibodies--potential clinical applications for tumor immunotherapy
    David A Schaer
    Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue, New York, NY 10065, USA
    Curr Opin Investig Drugs 11:1378-86. 2010
    ..This review discusses the role of GITR as a potential target for immunomodulatory therapy, as well as the research involved in understanding the mechanisms of anti-GITR therapy and current progress in translation into the clinic...
  2. ncbi request reprint Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 139:224-33. 2007
    ..Risk-adapted SCT with adjuvant thal/dex is feasible and results in low TRM and high haematological and organ response rates in AL patients...
  3. pmc Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity
    Adam D Cohen
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:4904-12. 2006
    ..Finally, this effect on vaccine-induced CD8(+) T-cell responses was partially independent of CD4(+) T cells (both helper and regulatory), consistent with a direct costimulatory effect on the effector CD8(+) cells themselves...
  4. pmc Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 5:e10436. 2010
    ..These findings provide further support for the continued development of agonist anti-GITR mAbs as an immunotherapeutic strategy for cancer...
  5. pmc Immune rejection of mouse tumors expressing mutated self
    Fei Duan
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:3545-53. 2009
    ..Immune modulation, such as inducing GITR signaling, is required to enhance CD8(+) T-cell responses to specific mutations and to lead to tumor rejection...
  6. pmc Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope
    David A Schaer
    Swim Across America Laboratory, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, New York, United States of America
    PLoS ONE 6:e21214. 2011
    ..Together, these data indicate that lack of anti-tumor efficacy is not solely due to ignorance of self antigen in the tumor microenvironment but rather to active immunosuppressive influences preventing a protective immune response...
  7. ncbi request reprint DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
    ..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD...
  8. pmc Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
    Jose A Guevara-Patino
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1382-90. 2006
    ....
  9. pmc OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
    Daniel Hirschhorn-Cymerman
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 206:1103-16. 2009
    ..Closer examination revealed that diminished intratumoral T reg cell levels resulted from hyperactivation and T reg cell-specific apoptosis. Thus, we propose that CTX and OX40 engagement represents a novel and rational chemoimmunotherapy...
  10. ncbi request reprint DNA vaccines against cancer
    Rodica Stan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Hematol Oncol Clin North Am 20:613-36. 2006
    ..It gives a brief history and then discusses the proposed mechanism of action, preclinical and clinical studies, and methods of enhancing the immune responses induced by DNA vaccines...
  11. ncbi request reprint DNA vaccines for melanoma
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Chemother Biol Response Modif 22:761-8. 2005
  12. ncbi request reprint High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
    Raymond L Comenzo
    N Engl J Med 358:92; author reply 92-3. 2008

Research Grants2

  1. Targeting GITR for Tumor Immunotherapy
    Adam Cohen; Fiscal Year: 2007
    ..Gaining greater mechanistic understanding of the effects of anti-GITR antibody on tumor immunity will allow for more rational translation of this promising immunotherapeutic approach to the clinic. ..